The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
DetermaIO identified patients who benefited from neoadjuvant immunotherapy resulting in improved pCR rate, independently of PDL1.
Authors
- Douglas Teller Ross (ORCID: https://orcid.org/0009-0009-8626-0244)
- Brock L. Schweitzer (ORCID: https://orcid.org/0000-0003-0178-5594)
- Begoña Bermejo (ORCID: https://orcid.org/0000-0001-7773-5994)
- Lajos Pusztai (ORCID: https://orcid.org/0000-0001-9632-6686)
- C. Zamagni (ORCID: https://orcid.org/0000-0002-7143-9091)
- Balázs Győrffy (ORCID: https://orcid.org/0000-0002-5772-3766)
- Chiun‐Sheng Huang (ORCID: https://orcid.org/0000-0002-6557-211X)
- Barbara Galbardi (ORCID: https://orcid.org/0000-0003-1424-421X)
- Robert S. Seitz (ORCID: https://orcid.org/0000-0002-5806-2840)
- Richard Greil (ORCID: https://orcid.org/0000-0002-4462-3694)
- Maurizio Callari (ORCID: https://orcid.org/0000-0001-5239-0918)
- Stefania Russo
- Daniel Egle (ORCID: https://orcid.org/0000-0003-0283-8176)
- Giampaolo Bianchini (ORCID: https://orcid.org/0000-0002-6790-6267)
- Tyler J. Nielsen (ORCID: https://orcid.org/0000-0002-9576-2838)
- Marco Colleoni (ORCID: https://orcid.org/0000-0002-5743-3013)
- Marc Thill (ORCID: https://orcid.org/0000-0002-8800-8044)
- Luca Gianni (ORCID: https://orcid.org/0000-0002-2372-9625)
- Pinuccia Valagussa (ORCID: https://orcid.org/0000-0003-3590-7916)
- Matteo Dugo (ORCID: https://orcid.org/0000-0001-9786-2763)
- Владимир Федорович Семиглазов (ORCID: https://orcid.org/0000-0003-0077-9619)
- Lucia Del Mastro (ORCID: https://orcid.org/0000-0002-9546-5841)
- Catherine M. Kelly (ORCID: https://orcid.org/0000-0001-8355-6714)
- Eva Ciruelos (ORCID: https://orcid.org/0000-0002-2796-1042)
- Gabriella Mariani (ORCID: https://orcid.org/0000-0001-7733-3143)
- Giuseppe Viale (ORCID: https://orcid.org/0000-0003-1882-7068)
- Antonio Antón (ORCID: https://orcid.org/0000-0002-2802-6232)
- Olivia Blasi
Institutions
- Semmelweis University (HU)
- Innsbruck Medical University (AT)
- Vita-Salute San Raffaele University (IT)
- Paracelsus Medical University (AT)
- Yale Cancer Center (US)
- Health University of Applied Sciences Tyrol (AT)
- BrustGesundheitZentrum Tirol (AT)
- Hospital Clínico Universitario de Valencia (ES)
- Fondazione Michelangelo (IT)
- Azienda Unità Sanitaria Locale di Ferrara (IT)
- Hospital Universitario 12 De Octubre (ES)
- Cancer Trials Ireland (IE)
- Hospital Universitario Miguel Servet (ES)
- Institute of Oncology NN Petrov (RU)
- Azienda USL di Bologna (IT)
- Ospedale Santa Maria della Misericordia di Udine (IT)
- National Taiwan University Hospital (TW)
- IRCCS Ospedale San Raffaele (IT)
- Ospedale Policlinico San Martino (IT)
- Agaplesion Markus Hospital (DE)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- INCLIVA Health Research Institute (ES)
- European Institute of Oncology (IT)
- University of Pecs (HU)
- HUN-REN Research Centre for Natural Sciences (HU)
- Incyte (United States) (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-0149
- Citations
- 17
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.80
Funders
- Breast Cancer Research Foundation
- Bristol-Myers Squibb
- Celgene
- F. Hoffmann-La Roche
- Associazione Italiana per la Ricerca sul Cancro